The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide What Is BPC 157? A Medical Clinic's Guide to the Body Protective Peptide, Its Uses, and What It Actually Does Perfect B The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions BPC 157: Miracle Healing Peptide or Hidden Danger?